Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428533 | 0.94 | CREBBP (0.33) | MAPK1 | |
| SCHEMBL24976105 | 0.94 | CREBBP (0.33) | MAPK1 | |
| SCHEMBL24976132 | 0.94 | ALDH1A1 (0.34) | ALDH1A1MAPTMAPK1HTTSMN1; SMN2 | |
| SCHEMBL31428785 | 0.91 | PDE9A (0.34) | ALDH1A1MAPTMAPK1HTTSMN1; SMN2 | |
| SCHEMBL31428765 | 0.89 | ALDH1A1 (0.32) | ALDH1A1MAPTMAPK1HTTSMN1; SMN2 | |
| SCHEMBL24975829 | 0.88 | MAPK1 (0.32) | MAPK1HSD11B1NR1H4 | |
| SCHEMBL31428620 | 0.88 | MAPK1 (0.32) | MAPK1HSD11B1NR1H4 | |
| SCHEMBL31428691 | 0.86 | UCHL1 (0.35) | HSD11B1 | |
| SCHEMBL24975804 | 0.85 | GRM2 (0.35) | EZH2HSD11B1NR1H4 | |
| SCHEMBL31428746 | 0.85 | GRM2 (0.35) | EZH2HSD11B1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | ALDH1A1 2352/4885MAPT 4513/4885MAPK1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.